IBDEI2N7 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44350,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,44350,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,44350,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,44351,0)
 ;;=D61.9^^200^2228^26
 ;;^UTILITY(U,$J,358.3,44351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44351,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,44351,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,44351,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,44352,0)
 ;;=D56.1^^200^2228^28
 ;;^UTILITY(U,$J,358.3,44352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44352,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,44352,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,44352,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,44353,0)
 ;;=C83.79^^200^2228^29
 ;;^UTILITY(U,$J,358.3,44353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44353,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,44353,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,44353,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,44354,0)
 ;;=C83.70^^200^2228^30
 ;;^UTILITY(U,$J,358.3,44354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44354,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,44354,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,44354,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,44355,0)
 ;;=D09.0^^200^2228^37
 ;;^UTILITY(U,$J,358.3,44355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44355,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,44355,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,44355,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,44356,0)
 ;;=D06.9^^200^2228^38
 ;;^UTILITY(U,$J,358.3,44356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44356,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,44356,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,44356,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,44357,0)
 ;;=D06.0^^200^2228^40
 ;;^UTILITY(U,$J,358.3,44357,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44357,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,44357,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,44357,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,44358,0)
 ;;=D06.1^^200^2228^41
 ;;^UTILITY(U,$J,358.3,44358,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44358,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,44358,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,44358,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,44359,0)
 ;;=D06.7^^200^2228^39
 ;;^UTILITY(U,$J,358.3,44359,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44359,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,44359,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,44359,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,44360,0)
 ;;=D04.9^^200^2228^42
 ;;^UTILITY(U,$J,358.3,44360,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44360,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,44360,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,44360,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,44361,0)
 ;;=C91.11^^200^2228^45
 ;;^UTILITY(U,$J,358.3,44361,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44361,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,44361,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,44361,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,44362,0)
 ;;=C91.10^^200^2228^46
 ;;^UTILITY(U,$J,358.3,44362,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44362,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,44362,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,44362,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,44363,0)
 ;;=C92.11^^200^2228^47
 ;;^UTILITY(U,$J,358.3,44363,1,0)
 ;;=^358.31IA^4^2
